P53-targeted therapies, MDM2 inhibitors, KRAS-targeted therapies, ATR inhibitors, IDH1 inhibitors, FGFR inhibitors, Her2-targeted therapies, and BRAF and MEK inhibitors are being investigated as targeted therapies for patients with CCA. Here, KRAS is linked to cholangiocarcinoma.